Wholomics

What Wholomics does

Wholomics is an Austrian privately-held company (Ried im Innkreis) founded in 2022 that develops NMR-based liquid biopsy tests for early cancer detection and precision medicine. Its core technology combines nuclear magnetic resonance spectroscopy with multi-omic biomarker analysis (metabolomic, proteomic, lipidomic) and machine-learning classification to identify disease-specific molecular signatures from a peripheral blood draw. The product portfolio consists of two investigational assays — a multi-cancer early detection (MCED) test covering 13 cancer types, and a dedicated pancreatic ductal adenocarcinoma (PDAC) early detection test — both currently designated Research Use Only and not CE-marked or FDA-cleared. Clinical validation has been presented at ASCO 2024 (PDAC, ~400 blinded patients), ASCO 2025 (MCED, 1,211 multi-center participants), and ASCO GI 2024, supported by collaborations with UMC Amsterdam, Masaryk University, CHU Namur, Biobank Antwerpen, Helmholtz München, University of Graz, IVO, and the Magnetic Resonance Institute.

The company's business model blends licensing/royalty income and research-grade testing services. Its primary named commercial channel is a technology-licensing agreement with Darwin AG (a publicly listed Munich-based healthcare company) that embeds Wholomics' AI algorithm in Darwin's NMR-based Multi-Cancer Check test, priced at €799 per test through Darwin's NovoMedic subsidiary. Wholomics is otherwise pre-revenue commercially, with its own assays sold only for Research Use Only. Go-to-market is B2B enterprise: direct engagement with healthcare providers, laboratories, and research institutions, supplemented by presence at ASCO, LSI USA, Web Summit, and Deep Tech Momentum conferences and accelerator support from aws First Inkubator (2022) and MassChallenge US (2024). The team of 1-10 employees is led by co-founders Patrick Strasser (CEO) and Maximilian Schneider (CTO), with Norbert Thumfart as CFO/Business Advisor, Dinah Kaylani-Ramkissoon leading Scientific Communications, and Dennis Hutchison advising on US commercial strategy and payer engagement. The company maintains a Boston office in addition to its Austrian headquarters.

Name

Wholomics

Legal name

Wholomics

Website

https://wholomics.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Wholomics is an Austrian privately-held company (founded 2022, 1-10 employees, with a Boston office) that develops NMR-based liquid biopsy tests combining metabolomic, proteomic, and lipidomic biomarkers with machine-learning classification for early detection of multiple cancers (including a dedicated pancreatic ductal adenocarcinoma assay), serving healthcare providers, research institutions, and licensing partners such as Darwin AG.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

Keywords

• Liquid biopsy diagnostics
• Multi-cancer early detection
• NMR-based biomarkers
• Precision oncology testing
• Cancer screening assays

Headquarters

HQ city

Ried Im Innkreis

HQ country

Austria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. MCED diagnostic testing services: Wholomics provides investigational blood-based multi-cancer early detection testing services, currently for Research Use Only while undergoing clinical validation. The company is working toward commercial adoption and scale.
2. Technology licensing - AI algorithm technology: Wholomics licenses its AI algorithm technology to partners such as Darwin AG for their NMR-based Multi-Cancer Check blood test detecting 13 cancer types.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Wholomics develops investigational, blood-based liquid biopsy tests that use NMR spectroscopy combined with AI/ML classification to detect molecular signatures associated with early-stage cancer. Its primary offerings are a multi-cancer early detection (MCED) assay covering 13 cancer types and a dedicated pancreatic ductal adenocarcinoma (PDAC) early detection test, both currently labeled Research Use Only and undergoing clinical validation. The underlying AI algorithm is also licensed to commercial partners such as Darwin AG.

Product overview

Wholomics offers a multi-cancer early detection (MCED) platform built on NMR-based multi-omics technology, combining metabolomic, proteomic, and lipidomic biomarker analysis with AI-powered machine-learning classification. The core portfolio consists of two investigational blood-test products: the Wholomics MCED Assay (a broad multi-cancer test detecting 13 cancer types) and the Wholomics Pancreatic Cancer Early Detection Test (a cancer-specific test validated for pancreatic ductal adenocarcinoma). Both products operate under a unified NMR-based molecular signature platform and are currently designated Research Use Only, undergoing ongoing clinical validation with no CE mark or FDA clearance. The platform is designed for scalable real-world clinical implementation via a simple, minimally invasive blood draw.

Differentiator

Problem solved

Functional benefit

Products and services

• Wholomics MCED Assay Investigational, blood-based multi-cancer early detection assay using NMR-based molecular signatures and AI to detect 13 cancer types at their earliest, most treatable stages; currently for Research Use Only and undergoing clinical validation, designed for clinical and laboratory integration.
• Wholomics Pancreatic Cancer Early Detection Test Proprietary blood-based early detection test for pancreatic ductal adenocarcinoma (PDAC) using NMR-based molecular signatures and computational biomarkers, validated in independent blinded cohorts including early-stage patients and those with precancerous or confounding conditions.
• Wholomics AI Algorithm Licensing Licensable AI algorithm technology that enables partners to run Wholomics' NMR-based multi-cancer detection classification on their own NMR-spectroscopy platforms; demonstrated through a partnership with Darwin AG for their Multi-Cancer Check blood test.

Quantifiable outcome

• Detected multiple cancers at Stage I with high accuracy in multi-center study of 1,211 participants (ASCO 2025)
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Darwin AGcoreStrategic or Co-development Partner · 1 April 2026Darwin AG, a Munich-based publicly listed healthcare company, partnered with Wholomics for AI algorithm technology. Darwin uses Wholomics' proprietary NMR-based molecular signatures in their Multi-Cancer Check blood test detecting 13 cancer types, offered at €799 per test in soft-launch through their Austria-based subsidiary NovoMedic.
• University Medical Center (UMC) AmsterdamcoreStrategic or Co-development PartnerResearch partnership for pancreatic cancer early detection studies. UMC Amsterdam provided clinical cohort of 104 participants for pilot study presented at ASCO GI 2024.
• Masaryk UniversitycoreStrategic or Co-development PartnerAcademic research partner collaborating on early cancer detection technology and validation studies.
• CHU NamurcoreStrategic or Co-development PartnerClinical research partner for early cancer detection studies and validation cohorts.
• Biobank AntwerpencoreStrategic or Co-development PartnerBiobank partner providing sample repositories for retrospective analysis in pancreatic cancer validation studies.
• Helmholtz Zentrum MünchencoreStrategic or Co-development PartnerLeading German research center partnership for translational cancer research and early detection technology development.
• University of GrazcoreStrategic or Co-development PartnerAcademic partner for cancer research collaboration and technology development.
• Institute for Oncology Research (IVO)coreStrategic or Co-development PartnerOncology research institute partnership for clinical validation and translational research in early cancer detection.
• Magnetic Resonance Institute (MRI)coreTechnology or IntegrationTechnical partnership for NMR/magnetic resonance technology implementation and analysis protocols.
• MassChallengeminorOthersAccepted to MassChallenge US Early Stage Accelerator program providing access to resources, mentorship, networking, and industry connections for startup growth.
• Amazon Web Services (aws First Inkubator)minorOthersAccepted to aws First Inkubator program providing funding, mentorship, networking, and access to latest technology and tools for development of innovative cancer screening tests.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Universal Diagnostics: European-based early-stage company developing blood-based MCED tests using mass spectrometry-based metabolomics and other novel biomarkers. It is an emerging peer using a non-DNA, signal-based detection approach conceptually aligned with Wholomics' NMR-based strategy.
• Owlstone Medical: Owlstone Medical is developing breath-based and blood-based tests for early disease detection including cancer, using novel non-invasive biomarker platforms. It is an emerging peer pursuing non-DNA, signal-based early cancer detection in adjacent modalities.
• Burning Rock Biotech: China-based liquid biopsy company developing NGS-based cancer detection and monitoring assays. It is an emerging peer in blood-based oncology diagnostics with a comparable B2B focus on cancer centers and research institutions.

Direct peers

• GRAIL: GRAIL's Galleri test is the leading commercial multi-cancer early detection (MCED) blood test, making it the most direct competitor to Wholomics' MCED assay. Both target early-stage multi-cancer detection via a single blood draw, though GRAIL relies on methylation-based ctDNA while Wholomics uses NMR-based multi-omics.
• Freenome: Freenome is developing a blood-based MCED assay using cell-free DNA and multiomics (genomic, epigenomic, proteomic) with machine learning. It is a direct peer pursuing the same multi-cancer early-detection market with a different multi-omics architecture.
• Exact Sciences: Exact Sciences offers Cologuard for colorectal cancer screening and acquired Thrive Earlier Detection to expand into MCED. It is a direct peer in blood-based cancer detection, with substantially greater commercial reach and capital than Wholomics.
• Thrive Earlier Detection: Originally an MCED spin-out (CancerSEEK) acquired by Exact Sciences, Thrive represents the DNA-mutation/protein biomarker approach to multi-cancer screening. It is a direct peer that illustrates both the strategic value and competitive pressure in the MCED category Wholomics targets.
• Guardant Health: Guardant Health is a leading liquid biopsy company offering blood-based cancer detection and monitoring tests (e.g., Guardant360, Reveal). It is a direct peer in the broader blood-based oncology diagnostics category relevant to Wholomics' liquid biopsy platform.

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is the largest IVD incumbent with broad oncology diagnostics and digital PCR/NGS capabilities. It is a broad incumbent that competes for the same clinical customers and could leverage scale to enter or acquire into the MCED space where Wholomics operates.
• Thermo Fisher Scientific: Thermo Fisher is a global life-sciences and diagnostics leader with mass spectrometry and clinical diagnostics offerings relevant to NMR/mass-spec-based biomarker detection. It is a broad incumbent whose instruments and CDx partnerships could enable or compete with Wholomics' NMR-based platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/wholomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wholomics